NASDAQ$SIBN

SI-BONE Inc · Q4 2024 earnings

Q4 2024 earnings · · After market close · Investor relations

Briefing

SI-BONE, Inc. reported record financial results for the fourth quarter of 2024, achieving 26% worldwide revenue growth and positive adjusted EBITDA.

SI-BONE, Inc. delivered a strong performance in Q4 2024, with worldwide revenue reaching $49.0 million, a 26% increase year-over-year, and achieving positive adjusted EBITDA of $1.9 million, marking a significant improvement from the previous year.

  • Worldwide revenue grew by approximately 26% to $49.0 million in Q4 2024.
  • U.S. revenue increased by approximately 28% to $46.9 million in Q4 2024.
  • The company achieved positive adjusted EBITDA of $1.9 million in Q4 2024, a 139% improvement.
  • Net loss improved by 59% to $4.5 million in Q4 2024.

Headline financials

Total Revenue

$49M

Previous: $38.9M+26.1%
EPS (adj)

-$0.11

Previous: -$0.27+59.3%
Gross margin

79.1%

Previous: 74.0%+6.9%
Adjusted EBITDA

$1.86M

Previous: -$4.81M+138.7%
Capital Expenditures

-$2.27M

Previous: $1.09M-307.3%
Net Income

-$4.5M

Previous: -$11M+59.1%
Operating Income

-$5.49M

Previous: -$12.5M+56.1%
Gross Profit

$38.8M

Previous: $28.7M+35.2%
R&D Expense

$3.87M

Previous: $4.16M-7.0%

Revenue & EPS history

SI-BONE · Revenue · Quarterly

$49M

Q4 2024+26.1%vs Q4 2023
Beat estimate in 10 of 15 quarters(67%)
ActualEstimate

Forward guidance

SI-BONE expects 2025 worldwide revenue to be in the range of $193.5 million to $195.5 million, implying year-over-year growth of 16% to 17%. The company anticipates gross margin between 77% and 78%, and operating expenses growth of approximately 9% at the mid-point of revenue guidance. Based on these assumptions, SI-BONE expects to deliver positive adjusted EBITDA for the second half and full year 2025.

Tailwinds

  • Anticipated worldwide revenue growth of 16% to 17% for 2025.
  • Expected gross margin in the range of 77% to 78% for fiscal year 2025.
  • Forecasted positive adjusted EBITDA for the second half and full year 2025.
  • Continued expansion of platform adoption.
  • Support from reimbursement tailwinds.

Headwinds

  • Operating expenses growth expected to be approximately 9% at the mid-point of revenue guidance.
  • Potential risks related to the ability to introduce and commercialize new products and indications.
  • Potential impact of future economic weakness on patient desire for elective procedures.
  • Risks in managing the supply chain.
  • Future capital requirements driven by new surgical systems.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q4 2024

Historical avgQ4 2024

-1.8%

Avg return

Earnings day

-1.3%

Avg return

5 days after

+0.0%

Avg return

30 days after

40%

12 / 30 earnings

Positive

+16.2%

Q4 2022

Best reaction

-23.7%

Q1 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-5.3%+15.3%+25.1%
Q4 2025-1.0%-0.6%-17.8%
Q3 2025+16.1%+11.1%+20.0%
Q1 2025+15.6%+29.8%+33.8%
Q4 2024+5.6%+3.7%-19.9%
Q3 2024-17.5%-18.8%-14.5%
Q2 2024-3.6%-5.2%+10.2%
Q1 2024+10.4%+8.0%-1.1%
Q4 2023-12.4%-15.7%-22.0%
Q3 2023-4.7%-12.4%-0.9%
Q2 2023-12.5%-9.6%-7.1%
Q1 2023+9.6%-0.3%+13.9%
Q4 2022+16.2%+19.5%+14.0%
Q3 2022-23.1%-16.4%-26.5%
Q2 2022-6.4%+0.1%+3.5%
Q1 2022-23.7%-27.6%-12.2%
Q4 2021+2.4%+3.2%+3.2%
Q3 2021-7.8%-10.9%-13.6%
Q2 2021-15.1%-18.9%-18.3%
Q1 2021-7.0%-7.5%-17.2%
Q4 2020+4.0%+6.6%+8.3%
Q3 2020+3.2%+0.5%+10.7%
Q2 2020+13.6%+17.7%+31.7%
Q1 2020+9.0%+11.9%+16.3%
Q4 2019-11.9%-21.7%-28.9%
Q3 2019-4.4%-4.5%-0.6%
Q2 2019+6.8%+10.7%+11.3%
Q1 2019-3.9%-8.1%-1.5%
Q4 2018-4.6%-3.6%-9.4%
Q3 2018-3.0%+4.8%+10.5%
Q2 2018
Q1 2018
Q4 2017
Q3 2017
Q2 2017
Q1 2017
Q1 2016
Q1 2015
Q4 2014
Q1 2014

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro